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ABSTRACT 
The study was to design a drug product to reduce the frequency of dosing, increase therapeutic effectiveness and improvement in patient 
compliance, by developing sustained release matrix tablet of Glimepiride using tamrind gum as a release modifier. In current study tamrind 
gum is used as a polymer which is investigated for sustained release carrier. The pre-formulation studies of drug excipient mixtures were 
performed. The tablets formulated were evaluated by physicochemical studies, in- vitro drug release, kinetic studies and stability studies. 
Drug and polymers has no interaction as observed by FTIR and UV studies. All the physicochemical parameters of tablets were found in the 
limits. Glimepiride is used in the treatment type II diabetes mellitus and is a first third generation sulphonyl urea agent. The drug release 
pattern was studied for extended period of 12 hrs for the optimized formulations. The release of drug under kinetic studies showed that it 
follows first order models. The different tablet formulations were put to stability studies and it was observed that there were no significant 
changes in release pattern, physicochemical parameters and drug content. The present study result indicates the suitability of the tamrind 
gum polymer in the preparation of sustained release formulations of glimepiride. 
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INTRODUCTION 
Oral Drug Delivery is the most favorable route of drug 
delivery due to patient compliance, ease of administration 
and dose flexibility of formulation. Most of the drug 
delivery system available in the market is oral drug 
delivery systems. Historically also the oral drug 
administration has been the predominant route for drug 
delivery as approximately 50% of the drug delivery 
systems available in market are oral drug delivery 
systems.1 
In recent years, natural polysaccharides are growing 
rapidly and it continues to remain and important in the 
new formulation development of the controlled released 
dosage form.2 Natural polysaccharides are much safer than 
synthetic. They provide many applications in the 
formulation development of a new controlled release 
dosage form, such as binder, disintegrator, diluents and 
release modifier.3 Therefore , they needs a  novel approach 
to enhance the use of natural polysaccharide in the 
formulation development of controlled released dosage 
form, because of the ease availability at an affordable price, 
high safety margin and higher productivity. Hence, the 
present study is aimed to enhance the use of natural plant 
based polymer such as tamrind as a release modifier to 
develop Glimepiride sustained release tablet. The purpose 
of this study is to investigate the sustain release properties 
of tamrind. These polymers were used as modifier using 
model drug Glimepiride.4 
 
Figure 1: Global Drug Delivery Market by mode of 
Administration
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MATERIAL & METHODS 
Materials 
Table 1: List of chemicals 
S.No. Ingredient Application 
1 Glimepiride Active pharmaceutical Ingredient 
2 Tamrind seeds Polymer 
3 Ethyl Cellulose Polymer 
4 MCC (Microcrystalline cellulose) Filler 
5 Lactose Diluents 
6 Talc Lubricants 
7 Magnesium Stearate Glidant 
 
Experimental Methods 
Preparation of tablet formulations by direct compression method 
Glimepiride tablet formulations were prepared by direct compression method.5-7 The drug and excipients were weighed 
accurately mixed properly with trituration and then matrix tablets were prepared by direct compression. Each tablet 
contains 8 mg of Glimepiride8. 
Table 2: Formulation development of Glimepiride by direct compression method 
Formulation 
code 
Glimepiride (mg) TSP (mg) Ethylcellulose (mg) MCC (mg) 
Magnesium 
Sterate (mg) 
F1 8 50 30 76 6 
F2 8 100 30 76 6 
F3 8 150 30 76 6 
F4 8 200 30 76 6 
F5 8 50 30 66 6 
F6 8 100 40 66 6 
F7 8 150 40 66 6 
 
Drug-excipient compatibility studies 
The pre-formulation during the development of solid 
dosage form the assessment of possible incompatibilities 
between an active drug substance and excipients.9 
Therefore, the pure drug and the formulations mixed with 
polymers were subjected to UV analysis and infra-red (IR) 
studies. 
Preformulation studies10 
Micromeritic properties11,12 
Angle of repose 
The funnel and cone method is  employed in which the 
funnel is fixed. The funnel is held with its tip at a given 
height, h, 2cm above graph paper. With r being the radius, 
of base of conical pile, angle of repose can be determined 
by following equation: 
θ = tan-1 (h / r) 
Where, θ is the angle of repose,  
h is height of pile;  
r is radius of base of the pile 
Bulk density and tapped density 
The flow property of granules was determined by bulk 
density and tapped density. A quantity measured about 
2gm of granules from each formula was introduced into 
the 10ml of measuring cylinder which was previously light 
shaken to break any agglomerates formed. After 
observation of initial volume, the cylinder was tapped 
down its own weight from the hard surface from a height 
of 2.5cm at 2 sec intervals.  
L B D and T B D were calculated using formulas: 
  Bulk Density = W / VO  
  Tapped Density = W / VF  
L B D: Weight of the powder/Initial volume of the packing 
T B D: Weight of the powder/Final volume of the packing 
Carr’s Compressibility Index (CI) 
Compressibility index is the measure that can be obtained 
from the bulk and tapped densities. A material having 
values of less than 20% has good flow property. The 
compressibility index was determined by Carr’s 
Compressibility index 
Carr’s index (%) = [(TBD-LBD) * 100] / TBD 
Where, 
L B D: Weight of the powder / Volume of the packing 
T B D: Weight of the powder / Tapped volume of the 
packing 
Evaluation of Glimepiride sustained release matrix 
tablets13,14 
Tablets were evaluated at various parameters such as 
weight variation, hardness, friability, drug content 
uniformity tablet and thickness, and in-vitro drug release 
with different media. 
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Weight variation 
This is performed to ensure that a tablet contains the 
proper amount of drug. The USP weight variation test is 
perform by weighing 20 tablets collectively and 
individually, calculating the average weight. I.P. official 
limits of percentage deviation of tablet. 
Tablet hardness: 
The hardness of the tablet is calculated to observe 
breakage under storage conditions. Monsanto hardness 
tester was used to check the hardness of each batch of 
tablet. The hardness was calculated in unit of kg/cm2. For 
testing hardness of batch of tablets, 5 tablets were chosen 
randomly and the average hardness of 5 determinations 
was recorded. 
Friability: 
Friability refers to loss in weight of tablets due to removal 
of fines from the surface of the tablets in the containers. 
Friability usually reflects poor cohesion of tablet 
ingredients. 
Tablet thickness: 
Vernier Callipers is used for calculation of thickness of 
tablets. It was determined by checking the thickness of ten 
tablets of each formulation batch. 
Drug content uniformity 
Drug content uniformity was calculated by using five 
tablets of each formulation and was weighed powdered. 
The quantity of powder was equivalent to 8 mg of the drug 
content. This equivalent weight of glimepiride was taken in 
the 100 ml volumetric flask and methanol was used as the 
extracting solvent and samples was analyzed 
spectrophotometrically by using UV/ Visible 
spectrophotometer at 228 nm.  
In Vitro-Release Testing 
Sustained release tablet formulation was subjected to In 
Vitro Release test by performing dissolution studies for all 
the formulations, employing 900ml of pH 6.8 phosphate 
buffer as the dissolution medium. The temperature of 37°C 
± 0.6°c was maintained by the medium used for dissolution 
studies.  
Stability studies  
Stability of a drug defined as the ability of a particular 
formulation in a specific condition, to remain within its 
physical, chemical, therapeutically and toxicological 
specification. The reason of stability testing is to evaluate 
the quality of drug formulation which varies with time 
under the influence of various environmental conditions 
such as temperature, humidity, light. 
RESULT & DISCUSSION 
Determination of λ max of Glimepiride 
The λ max of the Glimepiride was found to be 228 nm in 
methanol.
 
 
Figure 2: Glimepiride having λ max at 228 nm. 
 
Compatibility study 
Spectra of the pure drug, excipients and physical mixture 
were recorded in between 400 - 4000 wave number (cm-1). 
In the FTIR spectral analysis there is no appearance or 
disappearance of any characteristic peaks of pure drug 
glimepiride and in the physical mixture which confirms the 
absence of chemical interaction between drug and 
polymers.
 
Pure drug Peak       Physical mixture Pea 
NH stretching at  3363 cm-1    NH stretching at  3363 cm-1 
C-H stretching at  2942-2847 cm-1                     C-H stretching at  2938-2885 cm-1 
C=O stretching at  1711 cm-1    C=O stretching at  1712 cm-1 
C-N stretching  1542 cm-1    C-N stretching at  1543 cm-1 
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Figure 3: IR Spectra of the drug and formulation 
 
Micromeritic properties 
The pre-formulation studies was conducted by evaluation 
of granules by angle of repose, bulk and tapped density, 
compressibility index and Hausner’s ratio. Results of all the 
pre-compressional parameters performed on granules for 
formulations shown in Table No. 3 & 4. 
The range for angle of repose for the granules of all the 
formulations was found to be from 21º.28’±0.04 to 
26º.19’±0.05. The results of angle of repose (<30) indicates 
good flow properties of the powder. 
 
Table 3: Results of physical evaluation of Pre-compression blend using angle of repose. 
Formulation F1 F2 F3 F4 F5 F6 F7 
Angle of repose 
(Degree ± SD) 
22°.11’ 
±0.03 
21°.31’ 
±0.05 
24°.13’ 
±0.01 
26°.19’ 
±0.05 
21°.28’ 
±0.04 
25°.23’ 
±0.03 
26°.17’ 
±0.05 
 
Table 4: Results of physical evaluation of Pre-compression blend using density. 
Formulation F1 F2 F3 F4 F5 F6 F7 
Bulk Density 
(g/ml±SD) 
0.232 
±0.01 
0.219 
±0.03 
0.248 
±0.05 
0.231 
±0.07 
0.218 
±0.02 
0.229 
±0.04 
0.232 
±0.01 
Tapped Density 
(g/ml±SD) 
0.264 
±0.06 
0.260 
±0.02 
0.289 
±0.03 
0.260 
±0.01 
0.266 
±0.04 
0.262 
±0.02 
0.279 
±0.06 
 
Compressibility index range was found to be 11.92±0.07 to 
14.77±0.04 % for the granules of all the formulations. The 
Hausner’s ratio results were found to be lesser than 1.25 
which indicates better flow properties. This was further 
supported by lower compressibility index values. 
  
Table 5: Results of Pre-compression blend using Carr’s index & Hausner’s ratio. 
Formulations F1 F2 F3 F4 F5 F6 F7 
Carr’s Index 
(%± SD) 
14.63 
±0.03 
14.59 
±0.05 
13.09 
±0.04 
12.02 
±0.01 
12.64 
±0.03 
13.57 
±0.07 
11.32 
±0.03 
Hausner’s ratio 
(%± SD) 
1.18 
±0.01 
1.18 
±0.01 
1.14 
±0.03 
1.13 
±0.07 
1.16 
±0.01 
1.13 
±0.07 
1.15 
±0.03 
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Physical evaluation of tablets14 
Following organoleptic properties viz. colour, odour and 
shape were carried out after compression which 
demonstrated various quality control tests. All 
formulations (F1 to F7) were expressed as white, odorless, 
concave, round and flat.15 
Evaluation of prepared tablets15 
The tablets were evaluated with respect to hardness of 
different formulations and it was found uniform within the 
range of 3.25±0.21 to 4.01±0.43 kg/cm2. 
Tablet's strength of different formulations is measured by 
friability. Acceptable limit for conventional compressed 
tablets is that it loses of weight less than 1%. All the tablet 
formulations showed acceptable formulation technical 
properties.8,10
 
Table 6: Results of sustained release tablet formulations 
S.No. Formulation F1 F2 F3 F4 F5 F6 F7 
1 
Diameter 
(mm)± SD 
7.76 
±0.023 
7.85 
±0.001 
7.82 
±0.003 
7.91 
±0.013 
8.01 
±0.017 
7.89 
±0.018 
7.98 
±0.021 
2 
Thickness 
(mm)± SD 
3.7 
±0.01 
4.0 
±0.05 
4.1 
±0.03 
3.8 
±0.03 
4.0 
±0.08 
3.9 
±0.01 
4.1 
±0.05 
3 
Weight variation 
(mg) 
322.91 
±0.23 
323.73 
±0.71 
325.28 
±0.61 
325.75 
±0.24 
324.79 
±0.22 
322.56±
0.32 
323.79 
±0.59 
4 
Hardness 
(kg/cm2) 
7.4 
±0.01 
7.9 
±0.02 
8.0 
±0.02 
6.6 
±0.03 
6.9 
±0.01 
7.2 
±0.08 
6.2 
±0.08 
5 
Friability 
(%) 
0.63 
±0.005 
0.53 
±0.005 
0.61 
±0.024 
0.73 
±0.055 
0.64 
±0.021 
0.73 
±0.02 
0.56 
±0.00 
6 
Drug content 
(%) 
98.46 
±0.031 
100.12 
±0.011 
98.13 
±0.13 
99.77 
±0.076 
99.89 
±0.067 
98.91 
±0.088 
100.55 
±0.021 
 
In-vitro drug release study 
The formulated matrix tablets of glimepiride were 
evaluated by release profile as illustrated in table and 
figure. The in-vitro release of Glimepiride depends on 
swelling behavior of the tablets, higher the tablet swells 
the lesser amount of drug release. The in-vitro release 
study was performed in 0.1 N HCl for initial first 2 hrs, and 
then by phosphate buffer pH 6.8 and study was continued 
for 24 hour.14 
 
Table 7: In-vitro drug release profile of Glimepiride sustain release matrix tablets 
Time 
(Hrs) 
Drug Release (Cumulative percentage) 
F1 F2 F3 F4 F5 F6 F7 
0 0  0  0  0  0  0  0  
1 24.31±0.07  17.41±0.21  16.74±0.11  11.11±0.23  20.55±0.34  17.45±0.65  15.83±0.59 
3 57.27±0.07 34.32±0.08 32.35±0.17 31.22±0.41 38.21±0.17 34.15±0.01 32.29±0.16 
6 71.31±0.22 47.24±0.01 47.32±0.22 42.33±0.09 50.54±0.27 47.36±0.34 42.13±0.27 
9 90.61±0.17 67.37±0.43 64.87±0.39 58.47±0.21 71.88±0.06 68.34±0.63 63.23±0.33 
12 99.13±0.34 78.27±0.13 72.44±0.76 64.24±0.45 82.41±0.76 78.69±0.46 76.28±0.38 
15 -- 91.37±0.21 86.88±0.55 81.27±0.09 96.42±0.57 91.37±0.76 89.69±0.31 
18 -- 99.68±0.09 91.79±0.47 86.35±0.25 99.68±0.09 95.55±0.65 91.11±0.57 
21 -- -- 99.46±0.57 94.34±0.27 -- 99.88±0.58 95.43±0.31 
24 -- -- -- 99.32±0.32 -- -- 98.22±0.12 
 
 
Figure 4: Dissolution profile of Glimepiride for formulations F1 to F7  
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CONCLUSION 
On the basis of results of in-vitro drug release two best 
formulations F4 and F7 were selected as the best 
formulations. The formulations were subjected to various 
evaluation parameters like physical appearance, hardness, 
friability and drug content, invitro drug release. The 
outcome of the evaluation shows that there was no 
significant variation in result was observed in physical 
apprearance, hardness, friability, drug content and drug 
release during the whole duration of the study. It was found 
by three month stability studies that there was no significant 
change observed in the API. The inference is that 
formulations so prepared are physically and chemically 
stable. 
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